周五,Hims & Hers Health大跌超20%;同时,诺和诺德涨近4%。据美国食品药品监督管理局(FDA)称,诺和诺德旗下减肥药Wegovy和2型糖尿病药Ozempic中的活性成分司美格鲁肽已经摆脱短缺状态。
Hims & Hers Health生产司美格鲁肽的配方药,但美国法规规定,只有在该成分处于短缺状态时,该公司才能合法生产。因此,随着FDA宣布短缺结束,Hims & Hers在该领域的业务可能会受到一定影响。
诺和诺德表示:FDA批准的所有剂量的司美格鲁肽(semaglutide)正在持续出货,满足或超过预期的美国需求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.